全文获取类型
收费全文 | 26352篇 |
免费 | 1294篇 |
国内免费 | 253篇 |
专业分类
耳鼻咽喉 | 213篇 |
儿科学 | 513篇 |
妇产科学 | 620篇 |
基础医学 | 2769篇 |
口腔科学 | 523篇 |
临床医学 | 2283篇 |
内科学 | 7701篇 |
皮肤病学 | 565篇 |
神经病学 | 2314篇 |
特种医学 | 916篇 |
外科学 | 4298篇 |
综合类 | 62篇 |
一般理论 | 5篇 |
预防医学 | 951篇 |
眼科学 | 346篇 |
药学 | 1373篇 |
中国医学 | 43篇 |
肿瘤学 | 2404篇 |
出版年
2024年 | 27篇 |
2023年 | 224篇 |
2022年 | 462篇 |
2021年 | 777篇 |
2020年 | 486篇 |
2019年 | 642篇 |
2018年 | 764篇 |
2017年 | 586篇 |
2016年 | 722篇 |
2015年 | 785篇 |
2014年 | 998篇 |
2013年 | 1373篇 |
2012年 | 2119篇 |
2011年 | 2080篇 |
2010年 | 1220篇 |
2009年 | 1094篇 |
2008年 | 1906篇 |
2007年 | 1802篇 |
2006年 | 1648篇 |
2005年 | 1660篇 |
2004年 | 1522篇 |
2003年 | 1345篇 |
2002年 | 1244篇 |
2001年 | 158篇 |
2000年 | 110篇 |
1999年 | 160篇 |
1998年 | 219篇 |
1997年 | 200篇 |
1996年 | 154篇 |
1995年 | 183篇 |
1994年 | 149篇 |
1993年 | 139篇 |
1992年 | 87篇 |
1991年 | 74篇 |
1990年 | 87篇 |
1989年 | 52篇 |
1988年 | 46篇 |
1987年 | 38篇 |
1986年 | 49篇 |
1985年 | 51篇 |
1984年 | 56篇 |
1983年 | 41篇 |
1982年 | 53篇 |
1981年 | 32篇 |
1980年 | 43篇 |
1979年 | 25篇 |
1978年 | 15篇 |
1977年 | 17篇 |
1975年 | 19篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Valeria Cernaro Giuseppe Coppolino Luca Visconti Laura Rivoli Antonio Lacquaniti Domenico Santoro Antoine Buemi Saverio Loddo Michele Buemi 《Medicinal research reviews》2019,39(2):427-460
Erythropoiesis is triggered by hypoxia and is strictly regulated by hormones, growth factors, cytokines, and vitamins to ensure an adequate oxygen delivery to all body cells. Abnormalities in one or more of these factors may induce different kinds of anemia requiring different treatments. A key player in red blood cell production is erythropoietin. It is a glycoprotein hormone, mainly produced by the kidneys, that promotes erythroid progenitor cell survival and differentiation in the bone marrow and regulates iron metabolism. A deficit in erythropoietin synthesis is the main cause of the normochromic normocytic anemia frequently observed in patients with progressive chronic kidney disease. The present review summarizes the most recent findings about each step of the erythropoietic process, going from the renal oxygen sensing system to the cascade of events induced by erythropoietin through its own receptor in the bone marrow. The paper also describes the new class of drugs designed to stabilize the hypoxia-inducible factor by inhibiting prolyl hydroxylase, with a discussion about their metabolism, disposition, efficacy, and safety. According to many trials, these drugs seem able to simulate tissue hypoxia and then stimulate erythropoiesis in patients affected by renal impairment. In conclusion, the in-depth investigation of all events involved in erythropoiesis is crucial to understand anemia pathophysiology and to identify new therapeutic strategies, in an attempt to overcome the potential side effects of the commonly used erythropoiesis-stimulating agents. 相似文献
992.
993.
Miller J Colasurdo GN Khan AM Jajoo C Patel TJ Fan LL Elidemir O 《Pediatric pulmonology》2002,34(5):369-374
In this study, we evaluated immunocytochemical staining for milk proteins (alpha-lactalbumin and beta-lactoglobulin) in tracheal aspirates of mechanically ventilated infants, and assessed whether this staining technique supported a clinical diagnosis of aspiration in infants receiving orogastric feedings. All newborns requiring mechanical ventilation in the neonatal intensive care unit of a major tertiary care hospital were potential subjects for this study. Tracheal aspirates were obtained prior to the introduction of enteral feeding and at various time points thereafter in newborns requiring mechanical ventilation. Cells were obtained and processed for immunocytochemical staining of alpha-lactalbumin and beta-lactoglobulin. In total, 88 specimens recovered from 34 infants were adequate for staining. Alveolar macrophages recovered from most of the infants who were never fed (true negative controls) did not display immunoreactivity for milk proteins: 4/34 or 12% of infants' aspirates demonstrated presence of milk proteins before enteral feeding was commenced. Tracheal aspirates obtained from 12 infants after introduction of enteral feedings appeared to support clinical and radiological findings suggestive of aspiration events, with positive immunostaining on several occasions. These observations support our work in a murine model and demonstrate that immunocytochemical staining of tracheal aspirates for milk proteins may enhance the ability to diagnose pulmonary aspiration. Further studies are needed to define the clinical significance of our findings and the effects of single and repeated aspiration events on respiratory status. 相似文献
994.
Galbusera M Bresin E Noris M Gastoldi S Belotti D Capoferri C Daina E Perseghin P Scheiflinger F Fakhouri F Grünfeld JP Pogliani E Remuzzi G 《Blood》2005,106(3):925-928
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. The presence of anti-ADAMTS13 autoantibodies is considered a factor predisposing to relapses. Despite close monitoring and intensive plasma treatment, in these patients acute episodes are still associated with substantial morbidity and mortality rates, and the optimal therapeutic option should be prevention of relapses. This study was conducted in a patient with recurrent TTP due to high titers of ADAMTS13 inhibitors, who used to have 2 relapses of TTP a year. The study compared the standard treatment plasma exchange with rituximab. Results documented that plasma exchange had only a small transient effect on ADAMTS13 activity and inhibitors; on the contrary, prophylaxis with rituximab was associated with disappearance of anti-ADAMTS13 antibodies, a progressive recovery of protease activity, and it allowed the patient to maintain a disease-free state during a more than 2-year follow-up. 相似文献
995.
996.
Tamburino C Russo G Nicosia A Galassi AR Foti R Scriffignano V Kereiakes DJ Giuffrida G 《The Journal of invasive cardiology》2002,14(2):72-79
BACKGROUND: The use of abciximab (c7E3 Fab; ReoPro , Eli Lilly & Company, Indianapolis, Indiana) during percutaneous coronary intervention (PCI) decreases the incidence of early (30-day) and late (6-month to 1 year) adverse cardiac ischemic events. In a high-risk population, abciximab also reduced the need for target lesion revascularization. PCI of lesions with complex morphology, particularly long lesions, is associated with more complicated outcomes. The use of multiple and/or long intracoronary stents to cover long coronary lesions may lower the incidence of acute or subacute occlusion, but is still limited by a high late restenosis rate. We characterized patients undergoing elective implantation of long or multiple overlapping coronary stents and determined the impact of abciximab administration on clinical and angiographic outcomes. METHODS AND RESULTS: In a prospective, single-center randomized trial, a total of 107 patients undergoing elective implantation of long or multiple overlapping coronary stents were randomly assigned to receive either standard-dose heparin (n = 53) or abciximab plus low-dose heparin (n = 54). The use of abciximab was not associated with an increased incidence of bleeding or vascular complications compared to standard heparin regimen (3.7% versus 3.8%, respectively; p = NS). A 68% reduction in composite in-hospital cardiac events (i.e., death, myocardial infarction, urgent revascularization) was observed in the abciximab group (3.7% versus 11.5%, p = 0.1). At 6-month follow-up, a 48% reduction of target lesion revascularization (11% versus 21%; p = 0.1) and a decrease in binary angiographic restenosis were observed for abciximab-treated patients (17% versus 34%; p < 0.05). CONCLUSION: The peri-procedural use of abciximab during implantation of long or multiple overlapping coronary stents is safe and effective, as it does not increase bleeding or vascular complications compared to standard heparin anticoagulation and reduces the incidence of in-hospital adverse cardiac events; moreover, abciximab improves 6-month clinical and angiographic outcomes in such a complex setting. 相似文献
997.
998.
Rossana Taravell Marco Caruso Massimo Benedetto Renato Ciofalo Giuliana Pace Salvatore Asciutto Salvatore Novo Giuseppe Cirrincione 《老年心脏病学杂志》2016,13(12):1002-1004
MitraClip therapy for Mitral Regurgitation(MR) in advanced-endstage heart failure(HF),could open a final bridge to improve symptoms and quality of life in \"not transplantable\" patients.
We describe a homeless patient with NYHA class III HF, not elegible to heart transplantation for poor socio-economic status,and severe functional MR,treated with MitraClip. The patient was not suitable for conventional mitral valve repair because of high surgical risk and advanced HF (The STS mortality morbidity score=76%; EUROSCORE II=9,7%). Severe MR was confirmed at TEE preoperative evaluation of patient in which severe LV systolic dysfunction, diastolic dysfunction, severe right ventricle dysfunction, moderate tricuspid regurgitation and post-capillary pulmonary hypertension were detected. After 2 MitraClips implantation, TEE documented effective device position in relation to the main regurgitant jet, a MR grade reduction to 2 , with uneventful recovery. A gradual hemodynamic and general improvement was observed at three-month follow-up echocardiography documenting PAPs reduction and LVEF improvement. Beside, the patient showed HF symptoms reduction in NYHA class I-II. Management of functional MR in end-stage HF is an hard challenge, in addiction to the limited patient group feasibility and long-waiting list of heart transplantation. In the setting of this difficult current real-world experience, percutaneous tecnique was able to improve general conditions, quality of life and survival of our referred patient. 相似文献
999.
1000.
Diego Ardissino MD Stefano Savonitto MD Antonio Mussini MD Paola Zanini MD Alberto Rolla MD Paolo Barberis MD Marco Sardina MD Giuseppe Specchia MD 《The American journal of cardiology》1991,68(17):1587-1592
In 30 consecutive patients with Prinzmetal's angina pectoris, the antiischemic effect of felodipine, a new long-acting vasoselective calcium antagonist, administered at doses of 10 and 20 mg once daily was compared with that of the wellestablished therapeutic regimen with nifedipine administered at a dose of 20 mg 4 times daily. Twenty-four-hour Holter monitoring was performed during a 2-day placebo run-in and at the end of each of 3 consecutive 6-day periods during which the 3 active treatments were administered in randomized sequence. Three patients withdrew, whereas 27 completed the study. The therapeutic regimens tested proved to be similarly effective; primary end points (ischemic episodes recorded by Holter monitoring, and anginal attacks reported on diary cards) occurred in 5 patients (19%) during nifedipine treatment, and in 7 (26%) and 3 (11%) during felodipine treatment with 10 and 20 mg, respectively (p = not significant). The distribution of residual ischemic episodes demonstrated that treatment with felodipine once daily provides 24-hour antiischemic protection. Twenty-six patients were followed up with 20 mg of felodipine once daily for a mean of 6 ± 5 months, and 21 of them (81%) remained free of symptoms and Holter-recorded ischemic attacks. It is concluded that for Prinzmetal's angina pectoris, 24-hour antiischemic protection may be achieved with administration of felodipine once daily. The availability of a simplified therapeutic approach may constitute a real advantage in terms of patient compliance and improving the quality of life. 相似文献